(Bloomberg) — Alibaba Group Holding Ltd. (BABA) is trying to attract established brand names on Amazon.com Inc. (AMZN) to its global e-commerce site AliExpress, stepping up efforts to expand its footprint on the Seattle-based firm’s home turf. Most Read from Bloomberg AliExpress, Alibaba’s online retail portal for markets outside China, is trying to add more major brands by promising lower shipping fees and offering to take a lower cut of sales than Amazon does, according to people familiar with the ma ...

Group 1 - The company PropNotes specializes in identifying high-yield investment opportunities for individual investors [1] - PropNotes leverages a background in professional Prop Trading to simplify complex investment concepts and provide actionable insights [1] - The analysis produced by PropNotes aims to assist investors in making informed market decisions, supported by expert research [1] Group 2 - The article expresses the author's personal opinions and discloses a beneficial long position in OLPX shares [2] - The author confirms that they are not receiving compensation for the article, aside from that from Seeking Alpha [2] - There is no business relationship between the author and any company mentioned in the article [2] Group 3 - Seeking Alpha clarifies that past performance does not guarantee future results and does not provide specific investment recommendations [3] - The views expressed in the article may not represent those of Seeking Alpha as a whole [3] - Analysts contributing to Seeking Alpha may not be licensed or certified by any regulatory body [3]

Group 1 - The article provides a market analysis covering various financial instruments including Gold Spot US Dollar, US Dollar Index Futures, S&P 500 Futures, and Crude Oil WTI Futures [1]

Key Points Broadcom collaborates with end users to design chips for their needs. Broadcom signed a large new customer in Q3. The stock has gotten expensive in anticipation of huge growth. 10 stocks we like better than Broadcom › Nvidia (NASDAQ: NVDA) has been the undisputed king of artificial intelligence (AI) investing. Its products have been used to train and run AI models from the start, and they are still the computing unit of choice for many AI hyperscalers. However, there's a rising competi ...

Core Viewpoint - HSBC Holdings Plc considers the increase in visa costs for foreign employees in the US as "manageable" due to having fewer visa holders compared to peers and major technology companies [1][2]. Group 1: Visa Cost Impact - The Trump administration has raised the application fee for H-1B visas to $100,000, aimed at protecting American jobs and enhancing national security [3]. - This increase has caused concern among global companies, particularly in the technology sector, which heavily relies on the H-1B visa program for skilled workers [3]. - HSBC's corporate and institutional banking division head, Michael Roberts, indicated that the visa cost issue may be more significant for other financial services and tech firms [2][4]. Group 2: Company Position - HSBC has a relatively small number of visa holders, making the situation more manageable for the bank compared to larger firms like Amazon, Microsoft, and Meta, which hold the most H-1B visas [2][4]. - The bank experienced a surge of activity over the weekend following the announcement of the visa fee increase, similar to other companies [4].

FE fundinfo has purchased AlphaOmega, a Luxembourg firm that provides regulatory reporting services for investment managers. As per the terms of the deal, Antoine Capone from AlphaOmega will take up the role of general manager, Luxembourg, and join FE fundinfo’s leadership to assist with product work and client services across Luxembourg and other European markets. AlphaOmega offers regulatory output services for the EU, UK and Switzerland, consolidating reporting processes and applying regulatory tech ...

Dr. Sangmin Seo, known as Dr. Sam, is a blockchain pioneer and the visionary CEO and Chairman behind [Kaia DLT Foundation](https://www.kaia.io/), the force driving Asia’s largest Web3 ecosystem. With a strong technical background and leadership experience at Kakao’s blockchain ventures, he led the merger of Klaytn and Finschia blockchains to create Kaia. Today, Kaia powers seamless Web3 experiences integrated into everyday superapps like KakaoTalk and LINE, reaching over 250 million users across Asia. Fre ...

DUBAI, UAE, Sept. 22, 2025 /PRNewswire/ --Â Robo.ai Inc. (NASDAQ: AIIO) announces that it will establish a commercial vehicle joint venture with Pakistan's leading company JW Group, in furtherance of its strategic goal of contributing to green mobility and smart city development. ...

Key Points The U.S. government has been discussing whether to invest in defense stocks. One defense company that does a lot of business with the government is Lockheed Martin. An uptick in government spending could bolster Lockheed Martin's sluggish growth. 10 stocks we like better than Lockheed Martin › Last month, computer company Intel announced that the U.S. government was going to be taking a 10% stake in its business. The money would come from grants that it previously issued to the business ...

Group 1: Acquisition Details - Pfizer Inc. is nearing a $7.3 billion acquisition of Metsera Inc., a biotech firm focused on obesity treatments, with a cash offer of $47.50 per share and an additional $22.50 per share based on performance milestones [1] - The acquisition is part of Pfizer's strategy to re-enter the obesity drug market after previously discontinuing its own candidate due to safety concerns [3] Group 2: Metsera's Product and Market Position - Metsera, founded in 2022, is developing injectable and oral hormone analog peptides for obesity treatment, with its lead candidate, MET-097i, showing an average weight loss of 11.3% in mid-stage trials [2] - The drug's once-monthly dosing schedule may provide a competitive advantage over existing weekly GLP-1 injections [2] Group 3: Market Context and Future Outlook - The global demand for weight-loss therapies is projected to reach $150 billion by the early 2030s, positioning Pfizer to compete with major players like Eli Lilly and Novo Nordisk [3] - The deal highlights the increasing reliance of big pharma on biotech innovation to stay competitive in high-growth therapeutic areas [4]